| Ms Lisa Conti, MD | |
|
1025 New Moody Ln, Lagrange, KY 40031-9154 | |
| (502) 222-3886 | |
| (502) 222-8647 |
| Full Name | Ms Lisa Conti |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 37 Years |
| Location | 1025 New Moody Ln, Lagrange, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578652376 | NPI | - | NPPES |
| 1143378 | Medicaid | KY | |
| 64258775 | Medicaid | KY | |
| 000000194123 | Other | KY | KY ANTHEM #--GLAS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 25877 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Lagrange | La grange, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Greater Louisville Anesthesia Services, Pllc | 2264410661 | 13 |
News Archive
The Guardian examines the recent U.S. commitment to continue support for the development of Nigeria's health and education sector by Anne Fleuret, Nigeria's acting mission director of USAID.
An international research team led by the Research Institute of the McGill University Health Centre and Lund University has provided new evidence that aortic valve disease may be preventable.
TRANSCEND SERVICES, INC. a leading provider of clinical documentation services to the U.S. healthcare market, today announced its unaudited financial results for the third quarter ended September 30, 2010.
BioSante Pharmaceuticals, Inc. today announced the closing of the sale, directly to funds affiliated with two institutional investors, of an aggregate of approximately 10.4 million shares of BioSante's common stock and warrants to purchase up to approximately 5.2 million shares of its common stock, resulting in gross cash proceeds to BioSante of $18 million.
› Verified 2 days ago
| Entity Name | Greater Louisville Anesthesia Services, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326126681 PECOS PAC ID: 2264410661 Enrollment ID: O20040712001150 |
News Archive
The Guardian examines the recent U.S. commitment to continue support for the development of Nigeria's health and education sector by Anne Fleuret, Nigeria's acting mission director of USAID.
An international research team led by the Research Institute of the McGill University Health Centre and Lund University has provided new evidence that aortic valve disease may be preventable.
TRANSCEND SERVICES, INC. a leading provider of clinical documentation services to the U.S. healthcare market, today announced its unaudited financial results for the third quarter ended September 30, 2010.
BioSante Pharmaceuticals, Inc. today announced the closing of the sale, directly to funds affiliated with two institutional investors, of an aggregate of approximately 10.4 million shares of BioSante's common stock and warrants to purchase up to approximately 5.2 million shares of its common stock, resulting in gross cash proceeds to BioSante of $18 million.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Lisa Conti, MD 5927 Centerwood Dr, Crestwood, KY 40014-9196 Ph: (502) 241-3934 | Ms Lisa Conti, MD 1025 New Moody Ln, Lagrange, KY 40031-9154 Ph: (502) 222-3886 |
News Archive
The Guardian examines the recent U.S. commitment to continue support for the development of Nigeria's health and education sector by Anne Fleuret, Nigeria's acting mission director of USAID.
An international research team led by the Research Institute of the McGill University Health Centre and Lund University has provided new evidence that aortic valve disease may be preventable.
TRANSCEND SERVICES, INC. a leading provider of clinical documentation services to the U.S. healthcare market, today announced its unaudited financial results for the third quarter ended September 30, 2010.
BioSante Pharmaceuticals, Inc. today announced the closing of the sale, directly to funds affiliated with two institutional investors, of an aggregate of approximately 10.4 million shares of BioSante's common stock and warrants to purchase up to approximately 5.2 million shares of its common stock, resulting in gross cash proceeds to BioSante of $18 million.
› Verified 2 days ago